09:56 AM EST - Microbix Biosystems Inc. : And EMQN CIC a global supplier of laboratory external quality assessment schemes for human genomic testing, announce the go-live of a program to support rapid and accurate identification of patients who carry gene-variants associated with faster and slower than normal metabolism of the widely-prescribed antiplatelet (anti-clotting) drug Clopidogrel. Microbix Biosystems Inc.
shares T.MBX are trading unchanged at $0.27.
